Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
By D. Porter, B. Levine, M. Kalos, A. Bagg, C. June. New England Journal of Medicine, 2011
3,340 citations recorded by the source corpus.
SUMMARY We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose (approximately 1.5×105 cells per kilogram of body weight) of autologous chimeric antigen receptor–modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect.
Subfields: Genetics, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/f8b8dd254ae8adb2a6bb238d130a36268b2d03f5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- J. Kochenderfer
- Jennifer N. Brudno
- C. June
- S. Grupp
- Wendell A. Lim
- Michel Sadelain
- D. Porter
- S. Rosenberg
In Hematology
In Oncology
- J. Kochenderfer
- C. June
- Jennifer N. Brudno
- Michel Sadelain
- Wendell A. Lim
- S. Rosenberg
- N. Restifo
- R. Brentjens
Citations in the corpus
- Adoptive immunotherapy for cancer: harnessing the T cell response (2012, positive): “Gen mühendisliği bu tedaviye duyarlı tümör histolojilerinin çeşitliliğini büyük ölçüde arttırabilir; yeni literatürdeki birkaç örneği vermek gerekirse, bu çeşitlilik şimdilerde nörüblastom (77), sinovial hücre sarkomu (6), lösemi ve lenfoma (3, 5, 7) içermektedir.”
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015, positive): “In addition to using cytokine-blocking drugs, our group and others have used corticosteroids to treat CRS, as corticosteroids are effective in a number of diseases driven by activated T lymphocytes.(25,27,42,43) Corticosteroids are routinely used to treat and prevent CRS with blinatumomab.”
- Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, positive): “If the tumorassociated antigen towhich theCAR is targeted is expressed on normal tissues, those tissuesmaybedamaged, as is the casewithnormalB cells being depleted by anti-CD19 CAR T cells.8,16,31 CAR T cells may damage normal tissues by unexpectedly cross-reacting with a protein that is not express”
- Gene therapy clinical trials worldwide to 2012 – an update (2013, neutral): “42 10 transduced T cells [30].”
- The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “Patients successfully treated with CD19 CARs have profound B cell aplasia (Porter et al., 2011), and loss of B cell aplasia often heralds relapse (Kochenderfer et al., 2010).”